Literature DB >> 9175241

Protein S deficiency and antibodies to protein S in patients with Behçet's disease.

S Guermazi1, M Hamza, K Dellagi.   

Abstract

Thrombosis occurs in 20 to 30% of patients with Behçet's disease (BD). Most of the reported hemostatic abnormalities are related to the inflammatory syndrome. We have assessed the activity of antithrombin III, protein C and protein S (PS), in 30 patients with BD and in 30 healthy controls. Thrombosis antecedents were found in 16 patients. Antithrombin III and protein C were within the normal range, however free PS and PSactivity were significantly decreased in patients as compared to control group. PS deficiency detected in eight patients, was associated to thrombosis in 6 of them. No correlation was found between free PS/total PS ratio and C4bBP levels. Antibodies to PS were screened by ELISA and were present in 6 patients, associated to PS deficiency in 4, and to thrombosis antecedents in 5 cases. PS deficiency was transient in two patients, associated to a persistent antiPS in one of them. These findings suggest that auto-immune acquired PS deficiency may be involved in the pathogenesis of thrombotic events in BD.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175241     DOI: 10.1016/s0049-3848(97)00063-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  11 in total

1.  Serum vitronectin levels in patients with Behçet's disease.

Authors:  Ali Yalçındağ; Aslıhan Uzun; F Nilüfer Yalçındağ; Namık Delibaş
Journal:  Inflamm Res       Date:  2012-07-19       Impact factor: 4.575

2.  Haemostatic Parameters in Patients with Behçet's Disease.

Authors:  Juma K Alkaabi; David Gravell; Hamood Al-Haddabi; Anil Pathare
Journal:  Sultan Qaboos Univ Med J       Date:  2014-04-07

3.  Thrombosis in Behçet's disease: a Behçet's disease patient with complete thrombotic obstruction of IVC and both iliac veins and decreased protein S activity.

Authors:  Harin Jeong; In-Kyung Yoo; Sungjae Choi; Youngho Lee; Jongdae Ji; Gwankyu Song; Hwanhoon Chung; Seunghwa Lee; Won-Min Jo
Journal:  Rheumatol Int       Date:  2011-12-27       Impact factor: 2.631

4.  Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease.

Authors:  H Er; C Evereklioglu; T Cumurcu; Y Türköz; E Ozerol; K Sahin; S Doganay
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

5.  Specificity of anti-phospholipid antibodies in infectious mononucleosis: a role for anti-cofactor protein antibodies.

Authors:  M Sorice; V Pittoni; T Griggi; A Losardo; O Leri; M S Magno; R Misasi; G Valesini
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

6.  Immunoproteomic Identification of Noncarbohydrate Antigens Eliciting Graft-Specific Adaptive Immune Responses in Patients with Bovine Pericardial Bioprosthetic Heart Valves.

Authors:  Katherine V Gates; Qi Xing; Leigh G Griffiths
Journal:  Proteomics Clin Appl       Date:  2018-12-19       Impact factor: 3.494

7.  Activated protein C resistance in Behcet's disease.

Authors:  Hoda Abdel Badaee; Amr Edrees; Sherif Amin; Maher El Amir; Gaafar Ragab
Journal:  Thromb J       Date:  2013-09-02

Review 8.  The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy.

Authors:  Magdalena Paolino; Josef M Penninger
Journal:  Cancers (Basel)       Date:  2016-10-21       Impact factor: 6.639

Review 9.  New Insights into the Role of Tyro3, Axl, and Mer Receptors in Rheumatoid Arthritis.

Authors:  Sara Pagani; Mattia Bellan; Daniele Mauro; Luigi Mario Castello; Gian Carlo Avanzi; Myles J Lewis; Pier Paolo Sainaghi; Costantino Pitzalis; Alessandra Nerviani
Journal:  Dis Markers       Date:  2020-01-19       Impact factor: 3.434

10.  Analysis of receptor tyrosine kinase genetics identifies two novel risk loci in GAS6 and PROS1 in Behçet's disease.

Authors:  Jieying Qin; Lin Li; Donglei Zhang; Hongsong Yu; Handan Tan; Jun Zhang; Bolin Deng; Aize Kijlstra; Peizeng Yang
Journal:  Sci Rep       Date:  2016-05-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.